Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines (Hepatology International, (2021), 15, 6, (1421-1430), 10.1007/s12072-021-10263-x)

Wei Teng, Ting Tsung Chang, Hwai I. Yang, Cheng Yuan Peng, Chien Wei Su, Tung Hung Su, Tsung Hui Hu, Ming Lung Yu, Hung Chih Yang, Jaw Ching Wu

研究成果: Comment/debate同行評審

摘要

Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.

原文English
期刊Hepatology International
DOIs
出版狀態Accepted/In press - 2024

All Science Journal Classification (ASJC) codes

  • 肝病

指紋

深入研究「Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines (Hepatology International, (2021), 15, 6, (1421-1430), 10.1007/s12072-021-10263-x)」主題。共同形成了獨特的指紋。

引用此